Local therapies for advanced prostate cancer were associated with significantly more gastrointestinal and sexual issues in subsequent years than systemic treatments.
The combination, along with prednisone, is approved for adult patients with BRCA-positive castration-resistant prostate cancer, as determined by an FDA-approved test.
Men with newly diagnosed non-metastatic prostate cancer who were randomly assigned to surgery, radiation, or active monitoring had similar overall and prostate cancer-specific survival rates after 15 years.